These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1346 related items for PubMed ID: 28711727

  • 1. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B, Jakubowski AA, Papadopoulos EB, Fuller K, Hilden PD, Young JW, Barker JN, Koehne G, Perales MA, Hsu KC, van den Brink MR, Kernan NA, Prockop SE, Scaradavou A, Castro-Malaspina H, O'Reilly RJ, Boulad F.
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [Abstract] [Full Text] [Related]

  • 2. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
    Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB.
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):898-903. PubMed ID: 23467126
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R, Steinherz PG, Kernan NA, Prockop SE, Scaradavou A, Small TN, Shukla N, Khalaf R, O'Reilly RJ, Boulad F.
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [Abstract] [Full Text] [Related]

  • 5. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [Abstract] [Full Text] [Related]

  • 6. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, Inoue M, Koh K, Yabe H, Kawa K, Kato K, Atsuta Y, Kudo K.
    Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
    [Abstract] [Full Text] [Related]

  • 7. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH.
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [Abstract] [Full Text] [Related]

  • 8. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I, Mallouri D, Gavriilaki E, Batsis I, Kaliou M, Constantinou V, Papalexandri A, Lalayanni C, Vadikolia C, Athanasiadou A, Yannaki E, Sotiropoulos D, Smias C, Anagnostopoulos A.
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [Abstract] [Full Text] [Related]

  • 9. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA, Kim JH, Jeon YW, Yoon JH, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Kim HJ.
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [Abstract] [Full Text] [Related]

  • 10. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [Abstract] [Full Text] [Related]

  • 11. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A.
    J Hematol Oncol; 2017 Jan 24; 10(1):31. PubMed ID: 28118857
    [Abstract] [Full Text] [Related]

  • 12. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
    Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C.
    Biol Blood Marrow Transplant; 2018 Aug 24; 24(8):1651-1656. PubMed ID: 29753157
    [Abstract] [Full Text] [Related]

  • 13. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H, Fan ZP, Jiang QL, Huang F, Zhou HS, Zhang X, Yu GP, Wu MQ, Sun J, Liu QF.
    Zhonghua Nei Ke Za Zhi; 2012 Nov 24; 51(11):880-4. PubMed ID: 23291027
    [Abstract] [Full Text] [Related]

  • 14. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.
    Biol Blood Marrow Transplant; 2012 Mar 24; 18(3):466-72. PubMed ID: 21963618
    [Abstract] [Full Text] [Related]

  • 15. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ.
    Biol Blood Marrow Transplant; 2014 Apr 24; 20(4):549-55. PubMed ID: 24440648
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS, Rybicki L, Pohlman B, Bolwell B, Gerds AT, Hamilton BK, Hanna R, Kalaycio M, Majhail NS, Sobecks R.
    Hematol Oncol Stem Cell Ther; 2020 Sep 24; 13(3):160-165. PubMed ID: 31628924
    [Abstract] [Full Text] [Related]

  • 17. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.
    Biol Blood Marrow Transplant; 2002 Sep 24; 8(9):468-76. PubMed ID: 12374451
    [Abstract] [Full Text] [Related]

  • 18. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A.
    Bone Marrow Transplant; 2006 Feb 24; 37(4):339-44. PubMed ID: 16415898
    [Abstract] [Full Text] [Related]

  • 19. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, Baxter-Lowe LA, Luisi P, Militano O, Kletzel M, Cairo MS.
    Biol Blood Marrow Transplant; 2016 Apr 24; 22(4):698-704. PubMed ID: 26785332
    [Abstract] [Full Text] [Related]

  • 20. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G, Labopin M, Beohou E, Dalissier A, Dalle JH, Cornish J, Zecca M, Samarasinghe S, Gibson B, Locatelli F, Bertrand Y, Abdel-Rahman F, Socie G, Sundin M, Lankester A, Sedlacek P, Hamladji RM, Heilmann C, Afanasyev B, Hough R, Peters C, Bader P, Veys P.
    Biol Blood Marrow Transplant; 2017 Mar 24; 23(3):467-474. PubMed ID: 27916512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.